Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kunwha Pharmaceutical, now operating as Alvogen Korea after merging with Dream Pharma in June 2015, manufactures a wide range of generic pharmaceuticals including treatments for hypertension, hyperpotassemia, inflammation, pain relief, infections, cognitive disorders and prostate conditions. The company has several early-stage clinical programs such as oncology candidate KNW‑001 targeting farnesyltransferase and sustained-release sarpogrelate tablets in Phase I trials. Most marketed products are established generics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Alvogen Korea Co., Ltd..